К содержанию
Dr. Tara EinullaevaMedical oncologist

Treatment 8 min

Esophageal cancer: chemoradiotherapy, surgery and what comes after

Treatment of esophageal cancer: squamous cell carcinoma and adenocarcinoma, CROSS and FLOT regimens, definitive chemoradiotherapy, nivolumab after surgery, metastatic disease, nutrition and stenting.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 31 October 2026

Esophageal cancer is a disease in which treatment often consists of several stages: chemotherapy and radiotherapy, surgery, sometimes immunotherapy. The choice depends on the type of cancer (squamous cell carcinoma or adenocarcinoma), where the tumour is and how far it has spread. The right order of stages affects the result more than any single drug.

In this article I explain how the type and stage are determined, which regimens are used, when surgery can be avoided, what happens after surgery, how metastatic cancer is treated, how to cope with swallowing difficulty and when it is worth checking the plan with another specialist.

Two different diseases

Squamous cell carcinoma Adenocarcinoma
Where it is more common Upper and middle esophagus Lower esophagus and junction with the stomach
Associated with Smoking, alcohol, very hot food, poor nutrition Reflux, Barrett's esophagus, excess weight
Feature Responds well to radiotherapy HER2, MSI/dMMR, PD-L1, CLDN18.2 should be tested
Main regimens CROSS or definitive chemoradiotherapy CROSS or FLOT

For tumours at the junction with the stomach the principles of gastric cancer treatment also apply: chemotherapy for stomach cancer.

How the stage is determined

Several tests are usually required:

  • endoscopy with biopsy: confirms the diagnosis and tumour type;
  • endoscopic ultrasound: assesses depth of invasion into the wall and the nodes around the esophagus;
  • CT of the chest and abdomen and/or PET-CT: look for distant metastases and node involvement (what PET-CT shows);
  • for upper esophageal tumours, bronchoscopy to exclude invasion into the airway;
  • assessment of nutrition and lung and heart function, because surgery is major.

The stage is set by the TNM system (TNM in plain words). For adenocarcinoma biomarkers are also tested: HER2, MSI/dMMR, PD-L1 and, in advanced disease, CLDN18.2 (HER2, MSI and dMMR, PD-L1).

Early cancer: endoscopic treatment

If the tumour is superficial (involves only the mucosa and has no signs of spread to lymph nodes), it can be removed endoscopically: endoscopic mucosal resection or submucosal dissection. This avoids major surgery but requires accurate assessment of the depth of invasion in the removed specimen. If unfavourable features are found, additional surgery or chemoradiotherapy is discussed.

Resectable cancer: order of treatment

When the tumour has grown deeper but can still be removed surgically, the general principle is treatment before surgery to shrink the tumour and lower the risk of recurrence.

CROSS regimen

Preoperative chemoradiotherapy: weekly carboplatin and paclitaxel together with radiotherapy for about five weeks, then surgery after a few weeks. It is suitable for both squamous cell carcinoma and adenocarcinoma. More on the drugs: platinum drugs, paclitaxel.

FLOT regimen

Perioperative chemotherapy for adenocarcinoma: several cycles before surgery and several after. It includes oxaliplatin, docetaxel, leucovorin and 5-fluorouracil. This regimen is harder to tolerate but is well studied in adenocarcinoma of the lower esophagus and gastroesophageal junction. The choice between CROSS and FLOT depends on tumour location, general condition and centre preference.

Definitive chemoradiotherapy

For squamous cell carcinoma chemoradiotherapy is possible instead of surgery, with follow-up and the option of surgery if the disease returns. It is an option for cervical esophageal tumours (where surgery is too disruptive), for patients at high surgical risk and for those who have weighed the pros and cons carefully. The standard is radiotherapy of about 50 Gy with chemotherapy (cisplatin with 5-fluorouracil, or carboplatin with paclitaxel, or FOLFOX).

Nivolumab after surgery

In the CheckMate 577 trial, in patients who had preoperative chemoradiotherapy and surgery but still had living tumour in the removed specimen, nivolumab for a year lowered the risk of recurrence. So it is important to look at what the post-operative pathology report says: whether residual tumour is present and what the treatment-related pathological response is (pathological response). On immunotherapy: immunotherapy.

Surgery

The typical operation is esophagectomy: removal of the affected part of the esophagus and the nodes around it, then creation of a new "esophagus" from the stomach (sometimes from bowel). There are several approaches (transthoracic, transhiatal, minimally invasive and robotic), and the choice depends on tumour location and the surgeon's experience. The result depends markedly on the centre's experience: such operations are best done where many are performed.

Main risks: anastomotic leak, pneumonia, heart rhythm problems, reflux, dumping syndrome and weight loss. Many can be reduced by preparation before surgery (nutrition, breathing exercises, stopping smoking).

After surgery: nutrition and recovery

  • Eat small portions 6–8 times a day, slowly, sitting upright, and do not lie flat for 1–2 hours after eating.
  • Early fullness, belching and reflux are possible. For reflux, raise the head of the bed.
  • Dumping syndrome (weakness, sweating, diarrhoea after eating) is eased by small frequent meals and limiting fast carbohydrates.
  • Weight usually falls in the first months; it is important to track it and discuss loss of more than 5–10%. More: nutrition during chemotherapy.

When the disease is advanced or has returned

In metastatic or inoperable cancer treatment is systemic, with the aim of prolonging life and preserving its quality.

First line:

  • in squamous cell carcinoma, chemotherapy (platinum with 5-fluorouracil) with immunotherapy: pembrolizumab (KEYNOTE-590 trial) or nivolumab with chemotherapy or with ipilimumab (CheckMate 648), depending on PD-L1;
  • in adenocarcinoma, chemotherapy (platinum with a fluoropyrimidine) plus immunotherapy with suitable PD-L1;
  • in HER2-positive adenocarcinoma, trastuzumab is added to chemotherapy, and by current data pembrolizumab too (trastuzumab);
  • in tumours of the gastroesophageal junction with CLDN18.2 and no HER2, zolbetuximab may be added where available;
  • in MSI-H/dMMR disease immunotherapy is especially effective.

Later: paclitaxel or docetaxel, irinotecan, ramucirumab with paclitaxel in adenocarcinoma, trastuzumab deruxtecan in HER2-positive disease. The decision depends on previous treatment and condition. See also palliative chemotherapy and clinical trials.

Swallowing difficulty: what to do

The tumour can narrow the esophagus, and this is one of the main problems. What helps:

  • soft and liquid food, high-calorie nutritional supplements, small frequent meals;
  • an esophageal stent gives quick relief of swallowing but does not treat the tumour and has risks, so it is discussed when no other route is possible;
  • a feeding tube (nasogastric tube or jejunostomy) helps avoid weight loss before and during treatment;
  • chemoradiotherapy itself often reduces dysphagia after a few weeks;
  • brachytherapy or other palliative radiotherapy to ease swallowing.

If you are losing weight, do not delay the conversation about nutritional support: wasting worsens tolerance and the result of treatment. Pain on swallowing can also be treated: pain relief in cancer.

Side effects of chemoradiotherapy

  • inflammation of the esophagus during radiotherapy (pain on swallowing); painkillers and mouth rinses are discussed;
  • nausea, fatigue, low white cells (fever on chemotherapy);
  • numb fingers on platinum and paclitaxel (neuropathy);
  • late effects of radiotherapy: narrowing of the esophagus, lung fibrosis, pericarditis. So follow-up with a doctor is needed after treatment.

What to ask your doctor

  • What type of cancer do I have and what is the stage? How was it confirmed?
  • Were HER2, MSI and PD-L1 tested?
  • Why this sequence of treatment (CROSS, FLOT, definitive chemoradiotherapy)?
  • Is surgery needed and which centre performs such operations regularly?
  • What happens after surgery if tumour remains in the specimen?
  • How will we support nutrition and weight?
  • When and how will the result be assessed?

When to seek urgent help

  • temperature of 38 °C or above;
  • inability to swallow even saliva or liquids;
  • cough or choking while eating, sudden chest or neck pain;
  • vomiting blood or black stool;
  • shortness of breath, swelling and pain in one leg (see thrombosis in cancer).

Can I get a second opinion

Yes, especially when you must choose between surgery and definitive chemoradiotherapy, when biomarkers have not been tested, or when only palliative treatment is offered without discussing a curative route. Prepare the pathology, endoscopy report, CT or PET-CT and treatment summaries: documents for a second opinion, preparing for a consultation. If you need a review, book a consultation: I study the documents in advance and send a written summary. General information: stomach and esophageal cancer.

Sources

  1. Esophageal Cancer Treatment (PDQ) — National Cancer Institute
  2. ESMO Clinical Practice Guidelines — ESMO
  3. Practical guidelines for drug treatment of malignant tumours — RUSSCO (Russian Society of Clinical Oncology)
  4. Clinical guidelines (Russia) — Russian Ministry of Health

Frequently asked questions

This article is for information only and does not replace a consultation with your treating doctor. Decisions about tests and treatment are made by the doctor who looks after you.